Vaxcyte, INC Form 4 insider transactions

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., sold 17,000 shares of common stock on August 5, 2026 for $55.00 per share.

Jim Wassil, CHIEF OPERATING OFFICER of Vaxcyte, Inc., sold 2,250 shares of common stock on August 3, 2026.

Andrew Guggenhime, PRESIDENT AND CFO of Vaxcyte, Inc., sold 10,000 shares of common stock on August 3, 2026.

Grant Pickering, CHIEF EXECUTIVE OFFICER and a Director of Vaxcyte, Inc., sold 18,198 shares of common stock on July 27, 2026.

John Markels, a Director of Vaxcyte, Inc., received 23,029 shares of common stock on July 16, 2026.

Vaxcyte, Inc. reports that President and CFO Andrew Guggenhime sold 10,000 shares of common stock under a pre-arranged trading plan.

Vaxcyte, Inc. (PCVX) Chief Operating Officer Jim Wassil reported transactions involving the sale of company stock under a pre-arranged trading plan.

Vaxcyte, Inc. CEO Grant Pickering has sold a significant number of common shares under a pre-arranged trading plan.

Vaxcyte CEO Grant Pickering reported transactions involving company stock, including the acquisition of shares at $1.79 and the disposition of shares at $52.51, executed under a Rule 10b5-1 trading plan.

Vaxcyte, Inc. reports insider transactions by President and CFO Andrew Guggenhime, involving the acquisition and disposition of common stock.

Vaxcyte, Inc. reports a Form 4 filing detailing director Carlos V. Paya's acquisition of restricted stock units and stock options.

Vaxcyte, Inc. reports that Director Olivier Brandicourt acquired 2,194 shares of common stock and was granted options for 11,034 shares.

Vaxcyte Director John Furey reported the acquisition of 2,265 shares of common stock and 11,389 stock options on June 15, 2026.

Vaxcyte, Inc. Director Jacks Lee acquired 2,265 shares of common stock and was granted options for 11,389 shares.

Vaxcyte, Inc. director Halley E. Gilbert reported transactions involving restricted stock units and stock options on June 15, 2026.

Vaxcyte, Inc. reports that Director Teri Loxam acquired shares and stock options on June 15, 2026.

Vaxcyte, Inc. Director Anne S. Drapeau reported a transaction involving the acquisition of 2,265 shares of common stock and the grant of stock options for 11,389 shares.

Vaxcyte, Inc. Director Heath Lukatch reported the acquisition of 2,265 shares of common stock and the grant of stock options for 11,389 shares.

Vaxcyte, Inc. reports that Chief Operating Officer Jim Wassil sold a significant number of company shares through a pre-arranged trading plan.

Vaxcyte Chief Operating Officer Jim Wassil sold 2,250 shares of common stock pursuant to a pre-arranged 10b5-1 trading plan.

Vaxcyte, Inc. reports a Form 4 filing detailing stock transactions by SVP, Finance & CAO Elvia Cowan, executed under a pre-arranged 10b5-1 trading plan.

Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported the sale of 2,250 shares of common stock, totaling approximately $131,000, executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's SVP of Finance and CAO, Elvia Cowan, sold 1,892 shares of common stock on March 17, 2026, through a pre-arranged 10b5-1 trading plan.

Vaxcyte's SVP of Finance and CAO, Elvia Cowan, reported significant equity transactions, including RSU grants and stock option exercises.

Vaxcyte's President and CFO, Andrew Guggenhime, reported the acquisition of restricted stock units and stock options, alongside shares disposed for tax obligations.

Vaxcyte CEO Grant Pickering reported significant equity transactions, including the acquisition of restricted stock units and stock options, alongside shares disposed for tax obligations.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, reported significant equity awards including restricted stock units and stock options.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported multiple equity transactions including RSU grants, stock option awards, and shares withheld for taxes.

Vaxcyte, Inc. CEO Grant Pickering reported a gift of 100,000 common shares to an irrevocable trust for estate planning purposes.

Vaxcyte President and CFO Andrew Guggenhime transferred 61,850 shares of common stock to a grantor retained annuity trust (GRAT) via ALG 2025 GRAT HOLDINGS LLC.